BIIB · Biogen Inc.
$177.342026-05-17Sector: Healthcare; Industry: Drug Manufacturers - General; Sub-Industry: Biotechnology
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$197
+11.2% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($197 · $189) Analysts Range ($143 · $250) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2021.Q4 | $11.0B | — | 25.4% | 2.9% | $2.7B | $568MM | $3.3B | 2.5% | — | 10.0% | $27.0B | $10.61 | — |
| 2022.Q4 | $10.2B | -7.4% | 28.4% | 17.6% | $2.4B | $356MM | $2.7B | 4.6% | — | 9.2% | $24.5B | $20.77 | — |
| 2023.Q4 | $9.8B | -3.3% | 21.3% | 10.4% | $1.9B | −$7.0B | −$5.1B | 4.6% | — | 6.8% | $30.8B | $7.91 | — |
| 2024.Q4 | $9.7B | -1.6% | 25.7% | 14.4% | $2.1B | −$556MM | $1.6B | 5.3% | — | 7.0% | $29.9B | $11.13 | — |
| 2025.Q4 | $9.8B | 1.4% | 19.1% | 7.7% | $1.7B | −$61MM | $1.7B | 5.0% | — | 5.9% | $28.4B | $8.82 | 13.9 |
| italics below = DCF projection · 10yr Rev CAGR: 1.7% |
| 2026.Q4 | $9.4B | +-3.9% | 19.1% | 8.9% | $1.6B | $0MM | $1.6B | 6.1% | $1.5B | 5.8% | $28.4B | $11.18 | 15.9 |
| 2027.Q4 | $9.4B | +-0.8% | 16.8% | 10.2% | $1.4B | $0MM | $1.4B | 6.3% | $1.2B | 5.0% | $28.4B | $9.59 | 18.5 |
| 2028.Q4 | $9.5B | +1.3% | 21.3% | 11.4% | $1.8B | −$355MM | $1.4B | 6.6% | $1.2B | 6.3% | $28.7B | $12.19 | 14.5 |
| 2029.Q4 | $9.6B | +1.7% | 21.5% | 12.6% | $1.8B | −$479MM | $1.3B | 6.8% | $1.0B | 6.3% | $29.2B | $12.35 | 14.4 |
| 2030.Q4 | $9.8B | +2.1% | 21.5% | 13.9% | $1.8B | −$612MM | $1.2B | 7.1% | $881MM | 6.2% | $29.8B | $12.43 | 14.3 |
|
| Term. Yr+ | $12.0B | 4.1% | 27.6% | 20.0% | $2.7B | −$1.3B | $1.4B | 8.6% | $15.4B | 8.6% | — | — | — |
Active scenario IV: $197 (+11.2% vs market)